New York, NY – Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Investigating the Efficacy, Safety, Serum Concentration, and Biomarker Profile of Dupilumab Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis

This study is currently recruiting participants.

Sponsor: Regeneron Pharmaceuticals

Information provided by: Rockefeller University Identifier: NCT01979016

Purpose: Dupilumab (also known as REGN668), a fully human monoclonal antibody, is directed against the IL-4 receptor alpha subunit (IL-4Rα), which is a component of IL-4 receptors Type I and Type II, as well as the IL-13 receptor system. The binding of dupilumab to IL-4Rα results in blockade of the function of both IL-4 and IL-13 signal transduction. The T cell-derived cytokines IL-4 and IL-13 play dominant roles in the induction and effector phases of inflammatory allergic diseases and are present in elevated levels in individuals with atopic diseases, including asthma and atopic dermatitis.

Name/Title of the Principal Investigator: Dr. Emma Guttman, MD/PhD

Contact Information: 
Saakshi Khattri, MD – Research Associate
1230 York Avenue
New York, NY  10065
Business number: 212-327-8354/8333
Fax number: 212-327-8232
Recruitment Office 1-800-782-2737

 For more information, please visit: